Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBeximco Pharma Regulatory News (BXP)

Share Price Information for Beximco Pharma (BXP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 37.50
Bid: 36.00
Ask: 39.00
Change: 0.00 (0.00%)
Spread: 3.00 (8.333%)
Open: 37.50
High: 37.50
Low: 37.50
Prev. Close: 37.50
BXP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Amendment to Notification of Preliminary Results

4 May 2016 07:00

RNS Number : 1319X
Beximco Pharmaceuticals Ltd
04 May 2016
 

BEXIMCO PHARMACEUTICALS LTD.

 

4th May, 2016

 

Amendment to Notification of Preliminary Results

 

Beximco Pharmaceuticals Ltd. ("BPL", "Beximco Pharma" or "Company"), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that, further to its press release of 21st April 2016, the full accounts for the 12 month period ended on 31 December 2015 will now be released on Monday 9th May 2016.

 

For further information please visit www.beximco-pharma.com or enquire to:

 

Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: +880 2 58611001, ext.20080

 

Md. Asad Ullah, FCS, Executive Director & Company Secretary

Tel; +880 2 58611891, +880 2 58612040, Ext 10140

 

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Sean Wyndham-Quin

Tel: +44 (0)20 3368 3551 / 3555

 

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0)20 3727 1000

 

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebulizer solutions, oral soluble films, etc. Ensuring access to quality medicines is the powerful aspiration that motivates 3,000 employees of the Company.

 

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of the US, Australia, Europe, Latin America and Canada, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in Africa, including South Africa, Mauritius, Kenya, Ghana, Ethiopia and Nigeria; Pacific Island; Latin and Central American countries; Middle East; Central Asia; South East Asia, including Singapore, Malaysia, Indonesia, Philippines and Hong Kong; Europe, including Germany, Austria and Romania; Australia etc.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORBLGDUUXGBGLX
Date   Source Headline
29th Jun 20077:03 amRNSFinal Results
29th May 20071:36 pmRNSRe: Exports
30th Apr 200712:13 pmRNSExports to Middle East
2nd Apr 20077:01 amRNSRe: Exports to Ghana
22nd Mar 20077:00 amRNSCommences Exports to Belize
14th Mar 20078:02 amRNSExports to Botswana Commenced
22nd Feb 20077:01 amRNSTrading Statement
12th Feb 20073:51 pmRNSDetention of Salman Rahman
20th Dec 20067:00 amRNSTrading update
10th Oct 200611:45 amRNSOSD Plant Update
21st Sep 20062:32 pmRNSProduct Development
31st Jul 20067:02 amRNSInterim Results
9th Jun 200612:16 pmRNSLaunches Bird Flu Drug
31st May 20063:20 pmRNSRe Fundraising
2nd May 20067:03 amRNSFinal Results
31st Mar 20067:01 amRNSProduct Launch
16th Dec 20057:01 amRNSTrading Statement
21st Oct 20057:00 amRNSAdmission to AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.